The Food and Drug Administration has reported that Sandoz has issued a recall for all units of two specific lots of Methotrexate Sodium, USP, 25 mg/mL, 40 mL vial injectable solution.
According to the federal agency, these products were deemed dangerous after it was noted that particulate matter was present in the vials. The issue was discovered during a routine examination of certain samples. As soon as the company noted the problem, it decided to issue this recall.
The products were distributed to physicians and health care professionals. The products are used in the treatment of certain diseases including severe psoriasis and rheumatoid arthritis. Most of neoplastic diseases can be treated with Methotrexate.
Sandoz has not received any complaints or reports of adverse reactions or illnesses associated with these products.
You can follow this link to read the full article published by the FDA.